女性磷酸核糖焦磷酸合成酶超活性的临床表现与分子特征
本研究描述一名16岁非裔美国女性因尿酸生成过多出现进行性痛风石、肾结石和急性肾衰竭,全外显子测序发现PRPS1基因新突变c.520G>A(p.G174R),该突变导致ADP对PRPS1的抑制作用减弱。既往报道的女性患者临床外显率高,平均血尿酸8.5(4.1)mg/dl,痛风患病率高,提示应对家族中所有女性进行基因筛查。
要点
- 女性PRPS1超活性临床外显率高,可出现严重痛风石和肾衰竭。
- 新突变c.520G>A(p.G174R)导致ADP对PRPS1抑制减弱。
- 有痛风石、儿童期痛风或严重痛风家族史的女性应考虑PRPS1突变分析。
核心结论
- PRPS1超活性在女性中临床外显率高,可表现为严重痛风及肾脏并发症。
- 建议对PRPS1超活性家族中所有女性进行基因筛查以指导临床管理和遗传咨询。
- 有痛风石、儿童期起病痛风或严重痛风家族史的女性应考虑PRPS1突变分析。
研究设计与样本
- 对受累女性及其父亲进行全外显子测序的病例研究。
- 研究对象包括一名16岁非裔美国女性患者及其家系成员。
主要发现
- 先证者出现进行性痛风石、肾结石和尿酸生成过多所致急性肾衰竭。
- 家族史包括母亲患痛风石性痛风并因肾结石进展至终末期肾病,姐妹患多关节痛风。
- 突变分析发现PRPS1基因新突变c.520G>A(p.G174R),该突变导致ADP对PRPS1的抑制作用减弱。
- 既往报道的女性PRPS1超活性患者平均血尿酸水平为8.5(4.1)mg/dl[506(247)μmol/l],痛风患病率高。
关键数值与推荐
- PRPS1超活性为X连锁 disorder,OMIM基因参考300661,特征为尿酸生成过多。
- 既往报道女性患者平均血清尿酸8.5(4.1)mg/dl[506(247)μmol/l]。
临床怎么用
- 对PRPS1超活性家族中所有女性进行基因筛查。
- 对痛风石性痛风、儿童期起病痛风或严重痛风家族史的女性考虑PRPS1突变分析。
局限性
- 本研究为病例描述,样本量有限。
- 女性PRPS1超活性既往被认为罕见且表现轻微,本研究提示临床认识需更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Phosphoribosylpyrophosphate synthetase (PRPS1) superactivity is an X-linked disorder characterized by urate overproduction Online Mendelian Inheritance in Man (OMIM) gene reference 300661. This condition is thought to rarely affect women, and when it does, the clinical presentation is mild. We describe a 16-year-old African American female who developed progressive tophi, nephrolithiasis and acute kidney failure due to urate overproduction. Family history included a mother with tophaceous gout who developed end-stage kidney disease due to nephrolithiasis and an affected sister with polyarticular gout. The main aim of this study was to describe the clinical manifestations of PRPS1 superactivity in women. METHODS: Whole exome sequencing was performed in affected females and their fathers. RESULTS: Mutational analysis revealed a new c.520 G > A (p.G174R) mutation in the PRPS1 gene. The mutation resulted in decreased PRPS1 inhibition by ADP. CONCLUSION: Clinical findings in previously reported females with PRPS1 superactivity showed a high clinical penetrance of this disorder with a mean serum urate level of 8.5 (4.1) mg/dl [506 (247) μmol/l] and a high prevalence of gout. These findings indicate that all women in families with PRPS1 superactivity should be genetically screened for a mutation (for clinical management and genetic counselling). In addition, women with tophaceous gout, gout presenting in childhood, or a strong family history of severe gout should be considered for PRPS1 mutational analysis.
引用
- Zikánová M, Wahezi D, Hay A, et al. Clinical manifestations and molecular aspects of phosphoribosylpyrophosphate synthetase superactivity in females. Rheumatology (Oxford). 2018. PMID: 30423175. doi:10.1093/rheumatology/key041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。